Valsartan
| Evidence Level: L4 | Predicted Indications: 6 |
Table of Contents
Valsartan: From Hypertension to Malignant Hypertensive Renal Disease
One-Sentence Summary
Valsartan is an angiotensin II receptor blocker originally used to treat hypertension. The TxGNN model predicts it may be useful for malignant hypertensive renal disease, but the supporting evidence is thin: no clinical trials and 1 publication (a preclinical study of a different drug) were found for this indication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hypertension (hypertensive disorder) |
| Predicted New Indication | Malignant hypertensive renal disease |
| TxGNN Prediction Score | 0.9997 |
| Evidence Level | L4 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known information, valsartan is an angiotensin II type 1 (AT1) receptor blocker. Its efficacy in hypertension is established, and mechanistically it may be applicable to malignant hypertensive renal disease.
Angiotensin II-driven vascular and renal injury is central to malignant nephrosclerosis, so blocking the AT1 receptor is a plausible approach and sits close to the original hypertension indication. The only retrieved paper, however, studies avosentan (an endothelin antagonist) in hypertensive nephropathy in rats, not valsartan. It therefore gives only indirect support.
Other predicted indications were also reviewed:
- Malignant renovascular hypertension (L4): A 2001 animal study found AT1 receptor blockade prevented lethal malignant hypertension. This is indirect preclinical support. Bilateral renal artery stenosis is a known safety concern for this drug class.
- Pulmonary hypertension due to lung disease/hypoxia (L4): Evidence is preclinical and mostly involves sacubitril/valsartan rather than valsartan alone.
- Chronic pulmonary heart disease (L4): One preclinical paper suggests angiotensin receptor-neprilysin inhibition attenuates right ventricular remodeling in pulmonary hypertension. The rest of the literature concerns heart failure.
- Pulmonary hypertension with unclear multifactorial mechanism, Braddock syndrome, Prinzmetal angina (L5): Prediction only, with no credible supporting evidence.
Clinical Trial Evidence
No clinical trials are registered for the lead predicted indication, malignant hypertensive renal disease.
For the sixth-ranked prediction, chronic pulmonary heart disease, one trial was retrieved, but it is only tangentially related:
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT02966665 | Phase 1 | Recruiting | 420 | Vascular function and exercise rehabilitation in hypertension; does not appear to test valsartan or target this indication |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 24368192 | 2014 | Preclinical (animal) | Pharmacological Research | Avosentan (endothelin antagonist, not valsartan) protected against hypertensive nephropathy in transgenic rats at doses that did not cause fluid retention |
Related literature for other predicted indications:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 11560862 | 2001 | Preclinical (animal) | Circulation | AT1 receptor blockade prevented lethal malignant hypertension, related to reduced kidney inflammation (malignant renovascular hypertension) |
| 32552157 | 2020 | Preclinical (animal) | J Am Heart Assoc | Sacubitril/valsartan attenuated right ventricular remodeling in pulmonary hypertension |
| 22377232 | 2012 | Preclinical (animal) | Diabetes Res Clin Pract | Valsartan inhibited the HIF-1α pathway and reduced renal interstitial fibrosis in diabetic rats |
| 36719525 | 2023 | Preclinical (animal) | Sleep & Breathing | Sacubitril/valsartan mitigated intermittent-hypoxia-related gut microbiota changes and aortic injury |
| 39210725 | 2024 | Post hoc RCT analysis | JAMA Cardiology | Sacubitril/valsartan and all-cause hospitalizations in heart failure (indirect relevance) |
India Market Information
Valsartan is marketed in India with 20 valid single-ingredient registrations. Approved indication text is not available in the data compiled for this report. Main authorizations:
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 58946 | Diovan 80 Tablet (Novartis India Ltd) | Strip of 14 tablets | Not specified |
| 64720 | Diovan 160 Tablet (Novartis India Ltd) | Strip of 28 tablets | Not specified |
| 36075 | Co-Diovan 80/12.5 Tablet (Novartis India Ltd) | Strip of 14 tablets | Not specified |
| 233540 | Valent 80 Tablet (Lupin Ltd) | Strip of 10 tablets | Not specified |
| 208126 | Starval 160mg Capsule (Sun Pharmaceutical Industries Ltd) | Strip of 10 capsules | Not specified |
Safety Considerations
Package insert warnings and contraindications were not available in the data compiled for this report. Please refer to the package insert for full safety information.
- Disease contraindications (from a knowledge graph, not label text): Items flagged include liver failure and liver disease, pancreatitis, gallbladder disease, angioedema (including hereditary and ACE/RAAS-blocker-induced forms), systemic lupus erythematosus, diabetes and diabetic ketoacidosis, gout, hypotensive disorder, anuria, impaired renal function, renal artery obstruction, neutropenia/agranulocytosis, and electrolyte or mineral disorders (potassium deficiency, hypercalcemia, nephrocalcinosis, phosphorus metabolism disease). These should be verified against the official label.
- Drug Interactions: 254 interactions were recorded. The Major interactions among those listed are with potassium bicarbonate and potassium chloride (risk of hyperkalaemia). Moderate interactions include hydrocortisone, eluxadoline, exenatide, polyethylene glycol with electrolytes, and numerous insulin products.
- Bilateral renal artery stenosis is a known safety concern for this drug class, which is directly relevant to the renovascular hypertension prediction.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is very high (0.9997), and the AT1-blockade mechanism is plausible. But there are no clinical trials, and the only retrieved paper is an animal study of a different drug. Evidence is at the L4 level for the top predictions and L5 for several others, so the score alone cannot justify moving forward.
To proceed, the following is needed:
- Clinical or valsartan-specific preclinical data in malignant hypertensive nephrosclerosis (and renovascular hypertension)
- Mechanism of action data to strengthen the mechanistic-link analysis
- Package insert warnings and contraindications from the Indian regulatory source, which are needed for safety screening
- A safety assessment for patients with renal impairment, renal artery stenosis, or hyperkalaemia risk, given the renal focus of the lead indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.